TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS). Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada. Patient recruitment into the trial is ongoing at Toronto General ...

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury in patients undergoing on-pump cardiac surgery. Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the ninth site to be activated globally for the study and the fourth site to recruit patients in Canada. Patient recruitment ...

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company’s human trial funding grants. The Offering is subject to certain conditions including, but ...